Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie Medlicott

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 17, 2024
<b>Intestine vs. Liver</b> <b>？</b> <b>Uncovering the Hidden major Metabolic organs of Silybin in Rats</b>Yuanbo Sun, Like Xie, Jing Zhang, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|January 2, 2023
Low dose or very low dose phenylephrine and cyclopentolate microdrops for retinopathy of prematurity eye examinations (The Little Eye Drop Study): a randomised controlled non-inferiority trialLisa Jean Kremer, Natalie Medlicott, Mary Jane Sime, et al.
Clinical and Experimental Immunology|August 11, 2023
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19Rohan Ameratunga, Emily Mears, Euphemia Leung, et al.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 17, 2024
<b>Intestine vs. Liver</b> <b>？</b> <b>Uncovering the Hidden major Metabolic organs of Silybin in Rats</b>Yuanbo Sun, Like Xie, Jing Zhang, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|January 2, 2023
Low dose or very low dose phenylephrine and cyclopentolate microdrops for retinopathy of prematurity eye examinations (The Little Eye Drop Study): a randomised controlled non-inferiority trialLisa Jean Kremer, Natalie Medlicott, Mary Jane Sime, et al.
Clinical and Experimental Immunology|August 11, 2023
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19Rohan Ameratunga, Emily Mears, Euphemia Leung, et al.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Pageof 2